Aims: Accumulated evidence indicates that cerebral metabolic features, evaluated by proton magnetic resonance spectroscopy ( 1 H-MRS), are sensitive to early mitochondrion dysfunction associated with mitochondrial encephalomyopathy (ME). The metabolite ratios of lactate (lac)/Cr, N-acetyl aspartate (NAA)/creatine (Cr), total choline (tCho)/Cr, and myoinositol (mI)/Cr are measured in the infarct-like lesions by 
| INTRODUCTION
Mitochondrial encephalomyopathy (ME) is a group of metabolic neuromuscular diseases caused by mitochondrial and/or nuclear gene mutations. Their clinical manifestations are frequently nonspecific, as symptoms may arise from the majority of organs. The central nervous system (CNS) and skeletal muscle are frequently involved in ME, due to their dependence on mitochondrion oxidative phosphorylation (OXPHOS).
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Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) are the most common subtype of mitochondrial disorders. It is widely recognized that most MELAS harbor an A-to-G transition mutation at nucleotide 3243 of the mitochondrial genome, leading to severe mitochondrial dysfunction and energy abnormalities. 2 An additional subtype of ME with several different clinical manifestations from MELAS is chronic progressive external ophthalmoplegia (CPEO), which contains a 4977-bp large-scale mtDNA gene deletion. 3, 4 The metabolic abnormalities and pathogenesis of MELAS remain unclear. Notably, the clinical signature of stroke-like episodes has not been fully examined. One potential theory has suggested mitochondrial neuronopathy as the underlying cause of MELAS. In the context of increased neuronal vulnerability, a state of episodic neuronal hyperexcitability may occur that in turn results in predisposition to migraines and progressive spread of stroke-like lesions. 5 However, this hypothesis has not been fully validated in the brain tissue in vivo.
Proton magnetic resonance spectroscopy (

H-MRS) is a noninva-
sive technique used to assess metabolite changes in the brain tissue in vivo. 6 A total of four major metabolic indices are presented in typical 
H-MRS images have been
shown to be associated with mitochondrion dysfunction. 12 However, a limited number of studies have investigated the correlation between 1 H-MRS metabolic abnormalities and mitochondrion histopathology in ME subjects. In addition, the cerebral metabolic abnormalities between ME subtypes of MELAS and CPEO patients have not been adequately examined.
It is well known that mitochondrial disorders may induce metabolic disturbances and mitochondrial dysfunction in non-CNS tissues such as skeletal muscle. 13 Mitochondrial histopathological abnormalities in ME are typically characterized by mitochondrial myopathy, whereas muscle biopsy is an important method used to assess the outcome of the diagnosis. Irrespective of the molecular background, abnormal mitochondrial proliferation is frequently present in ME. The extreme variant that leads to abnormal mitochondrial proliferation is referred to as ragged-red fibers (RRFs). This term describes the highly disrupted fibers noted with H&E and modified Gomori trichrome (MGT) staining.
As muscle biopsy is an invasive procedure and provides only limited information, additional reliable biomarkers are required to anticipate the progression of ME pathology.
The relationship between cerebral metabolic abnormalities and altered mitochondrion in skeletal muscle is not fully investigated. The changes of the brain metabolites in the two different ME subtypes of MELAS and CPEO are often ignored. In this study, the correlations be-
H-MRS-detected metabolic abnormalities in the brain and MErelated mitochondrion abnormalities in the muscle were examined.
MGT staining and immunohistochemical markers (antimitochondrial antibody, AMA) were used to represent the accumulation of abnormal mitochondrion proliferation (RRFs). Cytochrome c oxidase (COX) activity was used to represent the residual enzyme activity. Pathological
RRFs and COX were used to investigate the pathological basis of 1 H-MRS-detected metabolite alterations that are associated with ME subtypes. The potential applications of the metabolite alterations as prognostic biomarkers were further explored. MELAS and CPEO were selected as the two different subtypes of ME. Rare ME subtypes, namely myoclonus epilepsy with raged red fibers (MERRF) and neuropathy ataxia retinitis pigmentosa (NARP) and Leigh Syndrome (LS),
were excluded as the MRI findings reported by such cases were scarce and not specific. 
| METHODS
| Patient selection
| Clinical characterization
The demographic information of the patients was shown in Tables 1   and 2 . The mean interval between onset of symptoms and MR evaluation was 3.82 years (range, 0.5-10 years) in MELAS and CPEO patients (Table S1 ). The clinical symptoms were simplified according to the consensus mitochondrial disease criteria (MDC) scoring system (Table S2 ). The MDC was an improved consensus system which was established in 2006. 15 The MDC was based on a score evaluation that includes clinical signs and symptoms (I) (muscle presentation IA, CNS abnormalities IB, multisystem involvement IC), metabolic/imaging studies (II), and muscle histology (III). The common muscular symptoms in the ME patients were proximal muscle weakness, exercise intolerance, and muscular atrophy. The patients were not under any form of drug treatment and were ambulant, except one patient, who failed to survive during the study. 
| Pathological study (muscle biopsy)
The surgical muscle biopsy procedure was conducted as previously RRFs and COX-positive quantifications were represented as the average ratios of RRFs/total and COX+/total muscle fibers. The experiments were conducted in a randomized and blinded manner.
| Molecular analysis
All patients received genetic confirmation. Total mitochondrial DNA was extracted (eight skeletal muscle samples, twenty urinary sediment samples) using commercial DNA purification kits (Promega Corporation., Madison, WI, USA). The patient genotype was detected by polymerase chain reaction (PCR) amplification and sequencing to determine the presence or absence of mtDNA mutations, as previously described. 17 The gene mutation in MELAS syndrome was identified at position 3243 A>G of the mtDNA, whereas the large-scale mtDNA deletion in the CPEO syndrome was 4977 bp that occurs between nucleotides 8470 and 13 477 ( Figure S1 ).
| 1 H-MRS acquisition
Patients underwent multivoxels MRS on a 3.0T scanner (Achieva slice thickness=8 mm) was used for the MRS examinations. The field of view (FOV) was localized on a transverse T2-weighted image, on which the full width of the lesion was revealed. Voxels of the lesion and the opposite areas of the brain were selected for further analysis. The local magnetic field homogeneity was optimized using the pencil beam shimming algorithm (PB-auto) to achieve a water peak full width at half maximum of <20 Hz. Water suppression was carried out based on the prescan algorithm using the excitation mode. Spectra measurements of Lac, NAA, tCho, mI, and Cr were calculated using the Extended Workspace method (EWS; Philips Medical Systems, Eindhoven, Netherlands), and metabolite intensity ratios were calculated using Cr as an internal reference metabolite.
| Statistical analysis
Data were expressed as mean±SEM (standard error of the mean), and statistical analyses were conducted using SPSS 20.0 software (SPSS, Chicago, IL, USA 
| RESULTS
| Predictive value of cerebral metabolite levels in MELAS and CPEO
In this study, four different cerebral metabolic indices were evaluated namely, Lac/Cr, NAA/Cr, tCho/Cr and mI/Cr. Representative spectra of T2-weighted brain MRIs for voxels among healthy controls and patients with MELAS and CPEO (ipsilateral lesion and contralateral normal-appearing brain area) were shown in Figure 1A and B. The level of the metabolite ratio Lac/Cr was significantly elevated in MELAS patients compared with healthy control subjects, as demonstrated by the red areas (lesion) and pink areas (contralateral gray matter) in Figure 1B and C (MELAS vs controls: P<.05 for Lac/Cr).
In addition, the levels of the metabolite ratio Lac/Cr was further in- for tCho/Cr and mI/Cr).
Receiver operating characteristics curves were carried out to further evaluate the statistical significance of the aforementioned
Comparison of brain metabolite levels measured by 1 H-MRS in control, MELAS, and CPEO groups. Representative spectra (A) of T2 weighted brain MRIs, (B) for voxels in the occipital lobe of a patient with MELAS, with CPEO (both ipsilateral lesion and contralateral gray matter region that appears normal to the lesions) and a health control subject. Spectral resonances identified include total choline-containing compounds (tCho at 3.24 ppm), total creatine (tCr at 3.03 ppm), N-acetyl-l-aspartate (NAA at 2.02 ppm), lactate (Lac at 1.33 ppm) and myoinositol (mI at 3.56 ppm). Notably, a clearly visible Lac peak in the spectra from the MELAS and CPEO groups is observed that is not found in the spectrum of the healthy control subjects. All of the spectra were plotted using the same vertical axis. (C) Mean metabolite levels in ratios of NAA/ Cr, lac/Cr, tCho/Cr, and mI/Cr in the control, MELAS and CPEO groups (lesion and contralateral normal regions of brain respectively). (control, n=23; MELAS, n=19; CPEO, n=9). Significant differences relative to the control group are marked by asterisks (*P<0.05) and relative to the MELAS lesions group by pound ( 
| The correlation between mitochondrial dysfunction and cerebral metabolites in MELAS patients
As lactate is the biomarker of mitochondrial dysfunction, and NAA, tCho, mI are regarded as the biomarkers of cerebral metabolites in the brain tissue in vivo, it was hypothesized that mitochondrial dysfunction might lead to aerobic glycolysis (Lac accumulation), impaired neuronal viability (NAA decline) and glial cell proliferation (mI elevation). Collectively, the results indicated that the mitochondrial dysfunction in the brain impaired neuronal integrity in the MELAS patients.
| Muscle histopathology in MELAS and CPEO
The morphological hallmark of the mitochondrial disease is mitochondrial myopathy. 
| The correlation between cerebral metabolites and muscular RRFs percentages in the ME patients
As cerebral metabolites play an important role in mitochondrial metabolism and neuronal function, it was hypothesized that in vivo detection of these metabolites in the brain by 
| The correlation between cerebral metabolite of Lac/Cr or NAA/Cr and COX-positive fibers percentages in MELAS patients
In MELAS (as discussed in the preceding section on muscle biopsy),
RRFs and blood vessels stained strongly for COX, while in CPEO most
RRFs and vessel walls were COX negative. MELAS patients appeared to have a significant amount of residual respiratory chain activity (by implication, capacity to produce ATP) relative to CPEO patients.
However, MELAS exhibited more severe clinical phenotype compared with CPEO, 5 particularly of the signature stroke-like episodes.
Our results also demonstrated that the MELAS patients exhibited a lower NAA/Cr ratio compared with the CPEO patients, suggesting Among patients with MELAS, the reduced cerebral mitochondrion metabolism may represent distinct neurological deficits, such as migraine and stroke-like episodes under conditions of increased metabolic demand. 19, 20 The specific etiology for this association may be partially explained by the mitochondrial neuronopathy and neuronal vulnerability. 5 NAA is localized exclusively in neurons and synthesized in neuronal mitochondria. 21 Consequently, NAA is considered to be a marker of neuronal viability. NAA content is mainly regulated by the mitochondrial synthesis rate. 22 Thus, reduced concentration of brain NAA may be a marker of mitochondrial dysfunction. 23 In the present study, reduced NAA/Cr and negative association between Lac/Cr ratio Currently, preliminary diagnostic criteria for patients with suspected ME include the ratio of serum lactate following exercise/at rest, which is 2-fold higher during the early stages of the disease.
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However, the latter biomarker is not always reliable as serum lactate levels increase in other neuromuscular diseases due to muscle injury.
In addition, serum lactate is also significantly elevated in patients with CPEOs and may not distinguish MELAS from CPEO cases. This may drive a switch to an alternative energy source, namely, aerobic glycolysis instead of OXPHOS, resulting in the elevation of lactate (the end-product of glycolysis) and the reduction of ATP production.
The cells that are deprived of mitochondrial ATP production, have to increase mitochondrion proliferation and reprogram its metabolism as a secondary survival mechanism, in order to maintain sufficient ATP levels and cellular integrity. However, the occurrence of compensatory mitochondrial proliferation is abnormal and plays a significant role in the pathogenesis of ME, which presents as abscess RRFs in muscle biopsy. Thus, in the present study, it may be hypothesized that mitochondrial dysfunction is associated with elevated lactate, decreased NAA and abnormal mitochondrial proliferation.
In addition, the current study demonstrated a minimal increase of the tCho/Cr and mI/Cr ratios in the MELAS and CPEO patients compared with control subjects, although no significant difference was noted. The elevated tCho metabolite ratio is considered to reflect increased membrane turnover and phosphatidylcholine catabolism, whereas the elevated mI metabolite represents severe gliosis (astrocytes and microglia proliferation). Previous findings regarding the changes in the Cho/Cr and mI/Cr ratios in ME subjects are contradictory, and elevated and/or nonsignificant changes have been reported. 29 In the present study, no association with any aspect of the mitochondrial cytopathy was noted.
The data presented possess certain limitations. Firstly, MRS exhibit limited sensitivity for the detection of lactate (a lactate concentration of higher than 4.0 mmol/L is required). Furthermore, the sample size was too small to allow detection of minor differences between the ME patients and the control subjects. In addition, the definition of regions of interest was less than optimal to avoid the selection of brain regions with visible focal lesions. Lastly, a metabolite ratio relative to Cr may not fully reflect the accurate concentration of NAA. Previous studies on MELAS that employed absolute quantification 27 demonstrated that total Cr concentrations could be reduced in both lesions and normal brain tissues. In this study, the overall ratio of NAA/Cr was decreased, suggesting higher reduction in NAA and in the pathological changes associated with brain lesions.
Consequently, further 1 H-MRS studies are required to investigate the potential clinical applications of the metabolic abnormalities associated with the progression of ME.
In conclusion, the present study provides quantitative evidence 
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